A Nasal Treatment for COVID-19

Description

The goal of this study is to test an investigational new inhaled medication called Optate.

Conditions

COVID-19

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to test an investigational new inhaled medication called Optate.

A Novel Nasal Treatment for COVID-19

A Nasal Treatment for COVID-19

Condition
COVID-19
Intervention / Treatment

-

Contacts and Locations

Indianapolis

Riley Hospital for Children, Indianapolis, Indiana, United States, 46202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * positive rapid COVID-19 test
  • * Ordinal Scale for Clinical Improvement \< 3 (OSCI, Appendix 2) and/or
  • * Fever \> 100 degree F and/or
  • * Nasal congestion
  • * FEV1 (Forced Exhaled Volume) \< 55% predicted on the day of study procedures
  • * OSCI ≥ 3 (Objective Structured Clinical Exam)
  • * Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Indiana University,

Study Record Dates

2025-03-30